Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free SABSW Stock Alerts

SAB Biotherapeutics (SABSW) Financials

SAB Biotherapeutics logo
$0.01 0.00 (-20.13%)
As of 07/10/2026 03:55 PM Eastern
This is a fair market value price provided by Massive. Learn more.
Compare
Annual Income Statements for SAB Biotherapeutics

Annual Income Statements for SAB Biotherapeutics

This table shows SAB Biotherapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 20 -17 -19 -42 -34 13
Consolidated Net Income / (Loss)		 20 -17 -19 -42 -34 13
Net Income / (Loss) Continuing Operations		 20 -17 -19 -42 -34 13
Total Pre-Tax Income 		20 -17 -19 -42 -34 13
Total Operating Income		 21 -13 -29 -38 -43 -49
Total Gross Profit		 55 61 24 2.24 1.32 0.00
Total Revenue		 55 61 24 2.24 1.32 0.00
Operating Revenue		 55 61 24 2.24 1.32 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 35 74 53 40 44 49
Selling, General & Admin Expense		 6.77 17 16 24 14 15
Research & Development Expense		 28 57 36 17 30 34
Total Other Income / (Expense), net		 -0.44 -3.76 10 -4.12 8.81 62
Interest Expense		 0.47 -0.37 0.30 0.32 0.32 0.24
Interest & Investment Income		 0.03 0.02 0.07 0.58 1.29 1.43
Other Income / (Expense), net		 0.00 -4.15 10 -4.39 7.84 61
Basic Earnings per Share		 $0.79 ($0.63) ($4.31) ($7.64) ($3.68) $0.22
Weighted Average Basic Shares Outstanding		 25.39M 27.34M 4.35M 5.52M 9.26M 19.31M
Diluted Earnings per Share		 $0.74 ($0.63) ($4.31) ($7.64) ($3.68) ($0.79)
Weighted Average Diluted Shares Outstanding		 27.01M 27.34M 4.35M 5.52M 9.26M 61.34M
Weighted Average Basic & Diluted Shares Outstanding		 - 42.96M 50.40M 9.23M 9.29M 50.95M

Quarterly Income Statements for SAB Biotherapeutics

This table shows SAB Biotherapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -5.10 -23 -5.03 -7.34 -10 -11 -5.20 -10 45 -17 -19
Consolidated Net Income / (Loss)		 -5.10 -23 -5.03 -7.34 -10 -11 -5.20 -10 45 -17 -19
Net Income / (Loss) Continuing Operations		 -5.10 -23 -5.03 -7.34 -10 -11 -5.20 -10 45 -17 -19
Total Pre-Tax Income 		-5.10 -23 -5.03 -7.34 -10 -11 -5.20 -10 45 -17 -19
Total Operating Income		 -5.32 -19 -11 -10 -11 -10 -11 -9.73 -13 -16 -20
Total Gross Profit		 1.27 0.31 0.94 0.26 0.00 0.11 0.00 0.00 0.00 - 0.00
Total Revenue		 1.27 0.31 0.94 0.26 0.00 0.11 0.00 0.00 0.00 - 0.00
Operating Revenue		 1.27 0.31 0.94 0.26 0.00 0.11 0.00 0.00 0.00 - 0.00
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 6.59 19 12 10 11 10 11 9.73 13 16 20
Selling, General & Admin Expense		 2.57 15 4.19 3.64 3.48 2.67 3.11 2.74 3.71 5.04 6.60
Research & Development Expense		 4.02 4.30 8.15 6.82 7.83 7.45 7.66 7.00 8.97 11 13
Total Other Income / (Expense), net		 0.22 -3.98 6.36 2.87 0.96 -1.39 5.58 -0.38 58 -1.09 1.13
Interest Expense		 0.07 0.08 0.08 0.09 0.08 0.07 0.07 0.06 0.04 0.06 0.06
Interest & Investment Income		 0.01 0.48 0.50 0.37 0.28 0.14 0.06 0.01 0.66 0.70 1.05
Other Income / (Expense), net		 0.28 -4.39 5.94 2.58 0.76 -1.45 5.58 -0.33 58 -1.73 0.14
Basic Earnings per Share		 ($0.97) ($4.14) ($0.54) ($0.79) ($1.12) ($1.23) ($0.56) ($1.09) $0.50 ($0.87) ($0.35)
Weighted Average Basic Shares Outstanding		 5.24M 5.52M 9.24M 9.26M 9.26M 9.26M 9.29M 9.29M 10.66M 19.31M 53.56M
Diluted Earnings per Share		 ($0.97) ($4.14) ($0.54) ($0.79) ($1.12) ($1.23) ($0.56) ($1.09) ($0.21) ($0.87) ($0.35)
Weighted Average Diluted Shares Outstanding		 5.24M 5.52M 9.24M 9.26M 9.26M 9.26M 9.29M 9.29M 77.86M 61.34M 53.56M
Weighted Average Basic & Diluted Shares Outstanding		 52.32M 9.23M 9.23M 9.23M 9.23M 9.29M 9.29M 10.41M 47.61M 50.95M 76.46M

Annual Cash Flow Statements for SAB Biotherapeutics

This table details how cash moves in and out of SAB Biotherapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 6.26 27 -24 42 -48 1.60
Net Cash From Operating Activities		 10 1.99 -23 -25 -34 -45
Net Cash From Continuing Operating Activities		 10 1.99 -23 -25 -34 -45
Net Income / (Loss) Continuing Operations		 20 -17 -19 -42 -34 13
Consolidated Net Income / (Loss)		 20 -17 -19 -42 -34 13
Depreciation Expense		 0.38 1.49 3.17 3.65 4.71 2.99
Amortization Expense		 0.17 0.16 0.12 0.09 -0.15 -0.00
Non-Cash Adjustments To Reconcile Net Income		 1.52 5.73 -7.78 11 -2.44 -57
Changes in Operating Assets and Liabilities, net		 -12 12 -0.24 1.94 -2.30 -3.69
Net Cash From Investing Activities		 -13 -11 -2.09 -0.15 -12 -122
Net Cash From Continuing Investing Activities		 -13 -11 -2.09 -0.15 -12 -122
Purchase of Property, Plant & Equipment		 -13 -11 -2.17 -0.20 -0.34 -0.93
Purchase of Investments		 - - - 0.00 -37 -142
Sale of Property, Plant & Equipment		 0.01 0.00 0.08 0.04 0.00 0.00
Sale and/or Maturity of Investments		 - - - 0.00 26 21
Net Cash From Financing Activities		 8.98 36 1.05 67 -1.17 168
Net Cash From Continuing Financing Activities		 8.98 36 1.05 67 -1.17 168
Repayment of Debt		 -1.40 -1.09 -5.52 -1.03 -1.29 -0.28
Issuance of Debt		 0.66 2.84 1.24 0.77 0.52 169
Other Financing Activities, net		 -0.18 34 -2.34 60 -0.40 -0.15
Effect of Exchange Rate Changes		 - - - 0.02 - -0.21
Cash Interest Paid		 - - 0.29 0.25 0.37 0.24

Quarterly Cash Flow Statements for SAB Biotherapeutics

This table details how cash moves in and out of SAB Biotherapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 -5.35 54 -43 3.21 -8.07 -0.27 -3.26 -1.95 26 -19 10
Net Cash From Operating Activities		 -5.17 -13 -11 -7.72 -6.29 -9.53 -7.80 -7.15 -13 -17 -14
Net Cash From Continuing Operating Activities		 -5.17 -14 -11 -7.73 -6.28 -9.53 -7.80 -7.16 -13 -17 -14
Net Income / (Loss) Continuing Operations		 -5.10 -23 -5.03 -7.34 -10 -11 -5.20 -10 45 -17 -19
Consolidated Net Income / (Loss)		 -5.10 -23 -5.03 -7.34 -10 -11 -5.20 -10 45 -17 -19
Depreciation Expense		 0.96 0.92 1.96 1.03 0.95 0.76 0.76 0.75 0.74 0.74 0.73
Amortization Expense		 0.02 0.02 -0.06 -0.06 -0.03 0.00 0.00 0.01 -0.00 -0.02 0.03
Non-Cash Adjustments To Reconcile Net Income		 0.57 8.67 -4.87 -1.64 1.06 3.00 -4.42 1.25 -61 6.61 5.82
Changes in Operating Assets and Liabilities, net		 -1.62 -0.42 -2.76 0.28 2.09 -1.91 1.06 0.94 1.62 -7.25 -1.99
Net Cash From Investing Activities		 -0.04 -0.07 -31 11 -1.15 9.33 4.67 5.20 -130 -1.71 -66
Net Cash From Continuing Investing Activities		 -0.04 -0.07 -31 11 -1.15 9.33 4.67 5.20 -130 -1.71 -66
Purchase of Property, Plant & Equipment		 -0.09 -0.07 -0.13 -0.05 -0.10 -0.06 0.00 - - -0.93 -0.98
Purchase of Investments		 - - -31 -0.11 -4.80 -1.31 -0.07 -0.05 -130 -12 -139
Sale of Property, Plant & Equipment		 - - 0.00 - - - 0.00 - - - 0.00
Sale and/or Maturity of Investments		 - - 0.00 11 3.75 11 4.74 5.25 - 11 75
Net Cash From Financing Activities		 -0.14 68 -0.39 -0.32 -0.67 0.22 -0.17 -0.17 169 -0.04 90
Net Cash From Continuing Financing Activities		 -0.14 68 -0.39 -0.32 -0.67 0.22 -0.17 -0.17 169 -0.04 90
Issuance of Debt		 - - 0.00 - - 0.52 - - - 169 87
Other Financing Activities, net		 -0.03 60 -0.18 -0.10 -0.06 -0.06 -0.17 -0.04 169 -169 3.05
Cash Interest Paid		 0.06 0.07 0.07 0.08 0.15 0.07 0.07 0.06 0.04 0.06 0.06

Annual Balance Sheets for SAB Biotherapeutics

This table presents SAB Biotherapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 57 81 51 84 44 173
Total Current Assets		 34 50 22 59 24 101
Cash & Equivalents		 13 33 15 57 8.90 11
Short-Term Investments		 - - - 0.00 12 86
Prepaid Expenses		 1.28 2.64 1.49 2.34 2.98 3.51
Other Current Assets		 - - - 0.00 0.05 0.95
Plant, Property, & Equipment, net		 15 24 23 20 15 13
Total Noncurrent Assets		 7.24 6.63 5.56 5.30 5.04 58
Long-Term Investments		 - - - - 0.00 47
Noncurrent Note & Lease Receivables		 4.18 4.02 3.90 3.67 3.58 3.50
Other Noncurrent Operating Assets		 3.05 2.62 1.66 1.63 1.45 8.06
Total Liabilities & Shareholders' Equity		 57 81 51 84 44 173
Total Liabilities		 18 43 20 27 18 21
Total Current Liabilities		 11 26 15 11 7.98 11
Short-Term Debt		 0.54 1.80 0.77 1.05 0.28 0.00
Accounts Payable		 9.29 17 14 7.64 7.17 9.73
Other Current Liabilities		 1.14 7.64 0.62 0.80 0.54 0.95
Total Noncurrent Liabilities		 6.47 16 4.85 16 10 11
Other Noncurrent Operating Liabilities		 6.30 16 4.31 16 10 11
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 39 39 31 57 26 151
Total Preferred & Common Equity		 39 39 31 57 26 151
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 39 39 31 57 26 151
Common Stock		 51 68 84 153 156 268
Retained Earnings		 -12 -29 -48 -90 -124 -111
Treasury Stock		 - - -5.52 -5.52 -5.52 -5.52
Accumulated Other Comprehensive Income / (Loss)		 - - 0.00 0.03 -0.14 0.19

Quarterly Balance Sheets for SAB Biotherapeutics

This table presents SAB Biotherapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 28 71 62 54 38 30 183 248
Total Current Assets		 3.13 47 40 33 16 9.31 113 113
Cash & Equivalents		 2.43 14 17 9.17 5.64 3.69 29 21
Short-Term Investments		 - 30 20 21 7.21 2.02 81 87
Prepaid Expenses		 0.70 2.70 2.03 2.04 3.42 3.59 1.84 3.84
Other Current Assets		 - 0.19 0.22 0.10 0.02 0.00 0.56 1.56
Plant, Property, & Equipment, net		 21 18 17 16 15 14 13 14
Total Noncurrent Assets		 4.59 6.52 5.39 5.18 7.21 6.96 57 122
Long-Term Investments		 - 1.24 0.00 0.00 - - 51 110
Noncurrent Note & Lease Receivables		 3.72 3.65 3.63 3.60 3.56 3.54 3.52 3.47
Other Noncurrent Operating Assets		 0.86 1.63 1.76 1.58 3.65 3.42 2.93 8.17
Total Liabilities & Shareholders' Equity		 28 71 62 54 38 30 183 248
Total Liabilities		 13 19 16 17 17 18 18 21
Total Current Liabilities		 9.21 8.30 7.55 8.82 9.65 11 11 9.85
Short-Term Debt		 0.54 0.84 0.62 0.00 0.14 0.00 0.00 0.00
Accounts Payable		 6.38 6.41 6.23 8.18 8.58 9.71 9.81 8.93
Other Current Liabilities		 0.66 0.68 0.60 0.52 0.94 0.96 0.99 0.92
Total Noncurrent Liabilities		 3.87 10 8.22 8.08 7.06 7.44 7.58 11
Other Noncurrent Operating Liabilities		 3.87 10 8.22 8.08 7.06 7.44 7.58 11
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 15 53 46 37 21 12 165 227
Total Preferred & Common Equity		 15 53 46 37 21 12 165 227
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 15 53 46 37 21 12 165 227
Common Stock		 88 153 154 155 156 157 265 363
Retained Earnings		 -67 -95 -102 -113 -129 -139 -94 -130
Treasury Stock		 -5.52 -5.52 -5.52 -5.52 -5.52 -5.52 -5.52 -5.52
Accumulated Other Comprehensive Income / (Loss)		 - -0.06 -0.03 0.05 -0.11 -0.02 0.07 -0.22

Annual Metrics And Ratios for SAB Biotherapeutics

This table displays calculated financial ratios and metrics derived from SAB Biotherapeutics' official financial filings.

Metric 2020 2021 2022 2023 2024 2025
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 0.00 43,474,779.00 43,030,885.00 52,319,156.00 9,229,274.00 47,606,851.00
DEI Adjusted Shares Outstanding		 0.00 4,347,478.00 4,303,088.00 5,231,916.00 9,229,274.00 47,606,851.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -3.94 -4.36 -8.06 -3.70 0.28
Growth Metrics		 - - - - - -
Revenue Growth		 0.00% 10.21% -60.73% -90.63% -40.94% -100.00%
EBITDA Growth		 0.00% -175.29% 4.39% -154.85% 21.18% 149.40%
EBIT Growth		 0.00% -185.35% -5.36% -129.72% 17.40% 134.45%
NOPAT Growth		 0.00% -145.61% -115.91% -31.67% -12.70% -62.97%
Net Income Growth		 0.00% -185.22% -9.31% -125.14% 19.17% 138.92%
EPS Growth		 0.00% -185.14% -9.31% -125.14% 51.83% 78.53%
Operating Cash Flow Growth		 0.00% -80.14% -1,280.73% -7.08% -36.52% -30.57%
Free Cash Flow Firm Growth		 0.00% 0.00% -317.15% 69.78% -203.63% -52.58%
Invested Capital Growth		 0.00% -97.04% 2,061.32% -89.70% 207.40% 46.02%
Revenue Q/Q Growth		 0.00% 0.00% -27.12% -45.32% -12.58% -100.00%
EBITDA Q/Q Growth		 0.00% 0.00% 20.72% -66.41% 27.58% -28.73%
EBIT Q/Q Growth		 0.00% 0.00% 16.71% -57.32% 25.18% -33.32%
NOPAT Q/Q Growth		 0.00% 0.00% -1.82% -40.70% 17.12% -13.34%
Net Income Q/Q Growth		 0.00% 0.00% 16.40% -55.06% 25.15% -29.17%
EPS Q/Q Growth		 0.00% 0.00% 16.40% -55.06% 25.20% -144.89%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 12.41% -89.90% 10.25% -19.30%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% -5.82% -14.86% -27.82%
Invested Capital Q/Q Growth		 0.00% 0.00% -20.58% -86.66% -15.65% 123.40%
Profitability Metrics		 - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 0.00%
EBITDA Margin		 38.21% -26.10% -63.56% -1,729.27% -2,307.71% 0.00%
Operating Margin		 37.22% -22.00% -120.97% -1,700.56% -3,244.87% 0.00%
EBIT Margin		 37.22% -28.82% -77.33% -1,896.54% -2,652.20% 0.00%
Profit (Net Income) Margin		 36.42% -28.16% -78.40% -1,884.50% -2,579.03% 0.00%
Tax Burden Percent		 100.02% 99.97% 100.14% 100.00% 100.00% 100.00%
Interest Burden Percent		 97.84% 97.75% 101.25% 99.36% 97.24% 109.86%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 75.83% -67.18% -223.34% -278.94% -826.46% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 79.52% -35.88% -229.17% -234.06% -815.75% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 -24.26% 22.97% 169.49% 183.44% 744.54% 0.00%
Return on Equity (ROE)		 51.57% -44.21% -53.85% -95.51% -81.92% 14.96%
Cash Return on Invested Capital (CROIC)		 0.00% 121.33% -405.65% -116.29% -928.27% -762.99%
Operating Return on Assets (OROA)		 36.36% -25.49% -28.00% -62.98% -54.74% 0.00%
Return on Assets (ROA)		 35.58% -24.91% -28.39% -62.58% -53.23% 0.00%
Return on Common Equity (ROCE)		 51.57% -44.21% -53.85% -95.51% -81.92% 14.96%
Return on Equity Simple (ROE_SIMPLE)		 51.57% -44.47% -60.34% -73.64% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 21 -9.38 -20 -27 -30 -49
NOPAT Margin		 37.22% -15.40% -84.68% -1,190.39% -2,271.41% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -3.69% -31.30% 5.83% -44.89% -10.71% 75.90%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -45.68% -114.45% -32.31%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 12.26% 28.07% 68.54% 1,062.95% 1,057.26% 0.00%
R&D to Revenue		 50.52% 93.93% 152.44% 737.61% 2,287.62% 0.00%
Operating Expenses to Revenue		 62.78% 122.00% 220.97% 1,800.56% 3,344.87% 0.00%
Earnings before Interest and Taxes (EBIT)		 21 -18 -18 -42 -35 12
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 21 -16 -15 -39 -31 15
Valuation Ratios		 - - - - - -
Price to Book Value (P/BV)		 2.56 8.81 0.82 0.63 1.35 1.18
Price to Tangible Book Value (P/TBV)		 2.56 8.81 0.82 0.63 1.35 1.18
Price to Revenue (P/Rev)		 1.81 5.58 1.06 16.07 26.48 0.00
Price to Earnings (P/E)		 4.97 0.00 0.00 0.00 0.00 13.41
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 20.12% 0.00% 0.00% 0.00% 0.00% 7.46%
Enterprise Value to Invested Capital (EV/IC)		 3.25 376.48 0.67 0.00 2.65 4.32
Enterprise Value to Revenue (EV/Rev)		 1.59 4.96 0.49 0.00 10.99 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 4.17 0.00 0.00 0.00 0.00 2.29
Enterprise Value to EBIT (EV/EBIT)		 4.29 0.00 0.00 0.00 0.00 2.86
Enterprise Value to NOPAT (EV/NOPAT)		 4.29 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 8.81 151.89 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 17.82 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - -
Debt to Equity		 0.02 0.05 0.04 0.02 0.01 0.00
Long-Term Debt to Equity		 0.00 0.00 0.02 0.00 0.00 0.00
Financial Leverage		 -0.31 -0.64 -0.74 -0.78 -0.91 -0.92
Leverage Ratio		 1.45 1.78 1.90 1.53 1.54 1.22
Compound Leverage Factor		 1.42 1.74 1.92 1.52 1.50 1.34
Debt to Total Capital		 1.79% 4.45% 4.06% 1.80% 1.05% 0.00%
Short-Term Debt to Total Capital		 1.36% 4.45% 2.39% 1.80% 1.05% 0.00%
Long-Term Debt to Total Capital		 0.43% 0.00% 1.67% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 98.21% 95.55% 95.94% 98.20% 98.95% 100.00%
Debt to EBITDA		 0.03 -0.11 -0.09 -0.03 -0.01 0.00
Net Debt to EBITDA		 -0.56 2.38 0.90 1.43 0.67 0.00
Long-Term Debt to EBITDA		 0.01 0.00 -0.04 0.00 0.00 0.00
Debt to NOPAT		 0.03 -0.19 -0.06 -0.04 -0.01 0.00
Net Debt to NOPAT		 -0.58 4.03 0.68 2.08 0.68 0.00
Long-Term Debt to NOPAT		 0.01 0.00 -0.03 0.00 0.00 0.00
Altman Z-Score		 5.80 4.67 -1.11 -1.65 -4.94 4.97
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - -
Current Ratio		 3.11 1.90 1.47 5.45 2.98 9.46
Quick Ratio		 3.00 1.56 1.37 5.23 2.60 9.04
Cash Flow Metrics		 - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 17 -37 -11 -34 -51
Operating Cash Flow to CapEx		 78.64% 18.16% -1,122.45% -16,449.74% -10,167.77% -4,800.82%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -121.91 -35.24 -105.96 -213.90
Operating Cash Flow to Interest Expense		 21.33 0.00 -77.79 -79.67 -107.70 -186.05
Operating Cash Flow Less CapEx to Interest Expense		 -5.79 0.00 -84.72 -80.16 -108.76 -189.92
Efficiency Ratios		 - - - - - -
Asset Turnover		 0.98 0.88 0.36 0.03 0.02 0.00
Accounts Receivable Turnover		 2.69 4.26 3.52 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 3.72 3.11 1.01 0.10 0.08 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 135.92 85.68 103.58 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 135.92 85.68 103.58 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - -
Invested Capital		 27 0.80 17 1.78 5.48 8.01
Invested Capital Turnover		 2.04 4.36 2.64 0.23 0.36 0.00
Increase / (Decrease) in Invested Capital		 0.00 -26 17 -16 3.70 2.52
Enterprise Value (EV)		 88 302 12 -20 15 35
Market Capitalization		 100 340 25 36 35 178
Book Value per Share		 $1.54 $0.89 $0.72 $1.10 $2.81 $3.18
Tangible Book Value per Share		 $1.54 $0.89 $0.72 $1.10 $2.81 $3.18
Total Capital		 40 40 32 58 26 151
Total Debt		 0.71 1.80 1.31 1.05 0.28 0.00
Total Long-Term Debt		 0.17 0.00 0.54 0.00 0.00 0.00
Net Debt		 -12 -38 -14 -56 -20 -143
Capital Expenditures (CapEx)		 13 11 2.09 0.15 0.34 0.93
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 11 -14 -7.17 -7.42 -4.67 -6.22
Debt-free Net Working Capital (DFNWC)		 24 26 7.88 49 16 90
Net Working Capital (NWC)		 23 24 7.10 48 16 90
Net Nonoperating Expense (NNE)		 0.44 7.77 -1.50 16 4.07 -62
Net Nonoperating Obligations (NNO)		 -12 -38 -14 -56 -20 -143
Total Depreciation and Amortization (D&A)		 0.55 1.65 3.29 3.75 4.56 2.99
Debt-free, Cash-free Net Working Capital to Revenue		 20.50% -23.02% -30.00% -331.47% -353.31% 0.00%
Debt-free Net Working Capital to Revenue		 43.33% 41.94% 32.95% 2,194.93% 1,216.60% 0.00%
Net Working Capital to Revenue		 42.35% 38.99% 29.72% 2,148.00% 1,195.74% 0.00%
Earnings Adjustments		 - - - - - -
Adjusted Basic Earnings per Share		 $0.00 ($6.30) $0.00 ($7.64) ($3.68) $0.22
Adjusted Weighted Average Basic Shares Outstanding		 0.00 2.73M 0.00 5.52M 9.26M 19.31M
Adjusted Diluted Earnings per Share		 $0.00 ($6.30) $0.00 ($7.64) ($3.68) ($0.79)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 2.73M 0.00 5.52M 9.26M 61.34M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 4.30M 0.00 9.23M 9.29M 50.95M
Normalized Net Operating Profit after Tax (NOPAT)		 14 -9.38 -20 -27 -30 -34
Normalized NOPAT Margin		 26.05% -15.40% -84.68% -1,190.39% -2,271.41% 0.00%
Pre Tax Income Margin		 36.41% -28.17% -78.29% -1,884.50% -2,579.03% 0.00%
Debt Service Ratios		 - - - - - -
EBIT to Interest Expense		 43.82 0.00 -61.29 -134.68 -110.15 50.20
NOPAT to Interest Expense		 43.82 0.00 -67.12 -84.54 -94.34 -203.41
EBIT Less CapEx to Interest Expense		 16.70 0.00 -68.22 -135.17 -111.21 46.33
NOPAT Less CapEx to Interest Expense		 16.70 0.00 -74.05 -85.02 -95.40 -207.28
Payout Ratios		 - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for SAB Biotherapeutics

This table displays calculated financial ratios and metrics derived from SAB Biotherapeutics' official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 52,319,156.00 52,319,156.00 9,225,494.00 9,229,274.00 9,229,274.00 9,229,274.00 9,288,868.00 9,291,697.00 10,411,061.00 47,606,851.00 50,951,037.00
DEI Adjusted Shares Outstanding		 5,231,916.00 5,231,916.00 9,225,494.00 9,229,274.00 9,229,274.00 9,229,274.00 9,288,868.00 9,291,697.00 10,411,061.00 47,606,851.00 50,951,037.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.98 -4.37 -0.54 -0.79 -1.12 -1.23 -0.56 -1.09 4.37 -0.35 -0.37
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -64.69% -85.88% 62.55% 207.70% -100.00% -62.40% -100.00% -100.00% 0.00% 0.00% 0.00%
EBITDA Growth		 33.56% -224.98% 44.55% -11.87% -137.10% 52.09% -24.94% -39.88% 573.26% -56.83% -330.85%
EBIT Growth		 28.13% -198.58% 25.58% -11.45% -109.01% 50.74% 4.73% -32.12% 525.02% -52.69% -282.55%
NOPAT Growth		 31.82% -140.12% -53.89% -57.52% -112.47% 46.97% 5.43% 4.60% -60.16% -57.56% -85.64%
Net Income Growth		 27.89% -190.26% 31.66% -6.61% -102.84% 50.15% -3.40% -37.88% 539.11% -47.97% -263.09%
EPS Growth		 27.89% -190.26% 63.01% 41.91% -15.46% 70.29% -3.70% -37.97% 81.25% 29.27% 37.50%
Operating Cash Flow Growth		 34.74% -764.73% -569.48% -57.53% -21.75% 29.11% 27.47% 7.34% -107.41% -76.00% -83.03%
Free Cash Flow Firm Growth		 -94.68% 110.58% -393.78% -238.03% -122.19% -559.57% -96.30% 6.31% -832.79% -26.68% -89.60%
Invested Capital Growth		 -38.70% -89.70% -32.15% -25.29% -51.38% 207.40% 3.95% -33.02% -44.86% 46.02% 10.64%
Revenue Q/Q Growth		 1,381.98% -75.93% 209.69% -72.14% -100.00% 0.00% -100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 31.65% -449.51% 84.11% -87.42% -44.88% -11.05% 58.57% -109.84% 590.19% -136.80% -13.83%
EBIT Q/Q Growth		 26.15% -360.93% 76.58% -39.83% -38.49% -8.64% 54.72% -93.91% 545.51% -139.03% -13.46%
NOPAT Q/Q Growth		 17.81% -254.58% 39.65% 10.44% -10.86% 11.50% -7.63% 9.65% -86.11% 12.93% -26.81%
Net Income Q/Q Growth		 25.85% -347.97% 78.01% -45.96% -41.09% -10.10% 54.39% -94.63% 549.32% -137.10% -11.91%
EPS Q/Q Growth		 25.85% -347.97% 86.96% -46.30% -41.77% -9.82% 54.47% -94.64% 80.73% -314.29% 59.77%
Operating Cash Flow Q/Q Growth		 -5.48% -160.20% 20.05% 28.21% 18.47% -51.50% 18.20% 8.28% -82.48% -28.55% 14.93%
Free Cash Flow Firm Q/Q Growth		 64.60% -50.61% -272.12% 1.36% 73.54% -923.04% 26.48% 52.92% -163.44% -38.94% -10.03%
Invested Capital Q/Q Growth		 6.16% -86.66% 368.83% 12.49% -30.90% -15.65% 58.54% -27.52% -43.12% 123.40% 20.13%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -320.47% -7,317.29% -375.46% -2,526.07% 0.00% -9,323.47% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -420.00% -6,187.90% -1,205.90% -3,876.95% 0.00% -8,726.26% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -398.23% -7,626.92% -576.69% -2,894.65% 0.00% -9,991.63% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -402.59% -7,493.75% -532.06% -2,787.69% 0.00% -9,934.52% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 101.10% 98.25% 92.26% 96.31% 98.11% 99.43% 100.14% 100.50% 101.36% 96.36% 95.04%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -68.43% -1,015.00% -212.32% -685.73% 0.00% -2,222.55% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 -42.69% -987.15% -222.75% -684.85% 0.00% -2,211.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 9.95% 773.65% 163.06% 455.94% 0.00% 2,017.99% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -58.48% -241.35% -49.26% -229.79% 0.00% -204.56% 0.00% 0.00% 0.00% 14.96% -0.32%
Cash Return on Invested Capital (CROIC)		 -59.68% -116.29% -246.27% -262.36% -295.59% -928.27% -350.93% -333.10% -798.55% -762.99% -454.78%
Operating Return on Assets (OROA)		 -40.34% -253.28% -26.32% -165.36% 0.00% -206.23% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -40.78% -248.85% -24.28% -159.25% 0.00% -205.05% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -58.48% -241.35% -49.26% -229.79% 0.00% -204.56% 0.00% 0.00% 0.00% 14.96% -0.32%
Return on Equity Simple (ROE_SIMPLE)		 -178.37% 0.00% -75.47% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -3.73 -13 -7.97 -7.14 -7.92 -7.01 -7.54 -6.81 -13 -11 -14
NOPAT Margin		 -294.00% -4,331.53% -844.13% -2,713.87% 0.00% -6,108.38% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -25.74% -27.86% 10.43% -0.89% -15.07% -11.55% 8.20% -15.57% 60.58% -7.10% -4.23%
Return On Investment Capital (ROIC_SIMPLE)		 - -22.64% -14.86% -15.28% -21.45% -26.69% -35.00% -56.69% -7.68% -7.29% -6.16%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 202.83% 4,878.95% 443.49% 1,384.31% 0.00% 2,328.62% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 317.17% 1,408.94% 862.41% 2,592.64% 0.00% 6,497.63% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 520.00% 6,287.90% 1,305.90% 3,976.95% 0.00% 8,826.26% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -5.05 -23 -5.45 -7.62 -11 -11 -5.19 -10 45 -17 -20
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.06 -22 -3.55 -6.65 -9.63 -11 -4.43 -9.30 46 -17 -19
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 2.16 0.63 0.79 0.62 0.68 1.35 0.59 1.36 0.13 1.18 0.86
Price to Tangible Book Value (P/TBV)		 2.16 0.63 0.79 0.62 0.68 1.35 0.59 1.36 0.13 1.18 0.86
Price to Revenue (P/Rev)		 8.05 16.07 16.09 10.29 16.47 26.48 33.43 142.17 182.45 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.12 13.41 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 89.55% 7.46% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 2.32 0.00 0.00 0.00 0.00 2.65 0.00 1.68 0.00 4.32 0.00
Enterprise Value to Revenue (EV/Rev)		 7.59 0.00 0.00 0.00 0.00 10.99 0.00 92.36 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.29 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 2.86 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.04 0.02 0.02 0.01 0.00 0.01 0.01 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.23 -0.78 -0.73 -0.67 -0.62 -0.91 -0.77 -0.73 -0.95 -0.92 -0.93
Leverage Ratio		 1.76 1.53 1.48 1.48 1.57 1.54 1.48 1.58 1.17 1.22 1.15
Compound Leverage Factor		 1.78 1.50 1.36 1.42 1.55 1.53 1.48 1.59 1.19 1.18 1.10
Debt to Total Capital		 3.43% 1.80% 1.56% 1.32% 0.00% 1.05% 0.64% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 3.43% 1.80% 1.56% 1.32% 0.00% 1.05% 0.64% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 96.57% 98.20% 98.44% 98.68% 100.00% 98.95% 99.36% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 -0.02 -0.03 -0.02 -0.02 0.00 -0.01 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.08 1.43 1.24 1.00 0.00 0.67 0.40 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 -0.03 -0.04 -0.03 -0.02 0.00 -0.01 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.10 2.08 1.51 1.15 0.00 0.68 0.43 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 -2.51 -0.89 -0.08 -0.97 -2.14 -3.18 -4.53 -7.09 1.44 4.41 5.02
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 0.34 5.45 5.65 5.24 3.69 2.98 1.69 0.87 10.50 9.46 11.45
Quick Ratio		 0.26 5.23 5.30 4.94 3.45 2.60 1.33 0.54 10.27 9.04 10.90
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 4.72 2.33 -4.01 -3.96 -1.05 -11 -7.87 -3.71 -9.76 -14 -15
Operating Cash Flow to CapEx		 -6,057.97% -19,814.21% -8,328.56% -14,697.46% -6,273.21% -17,213.26% 0.00% 0.00% 0.00% -1,797.81% -1,454.69%
Free Cash Flow to Firm to Interest Expense		 67.67 29.91 -52.50 -42.47 -13.41 -151.06 -113.15 -57.59 -225.50 -213.73 -237.85
Operating Cash Flow to Interest Expense		 -74.14 -172.66 -140.76 -82.88 -80.63 -134.49 -112.09 -111.14 -301.44 -264.35 -227.45
Operating Cash Flow Less CapEx to Interest Expense		 -75.37 -173.53 -142.45 -83.44 -81.92 -135.27 -112.08 -111.14 -301.44 -279.06 -243.08
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.10 0.03 0.05 0.06 0.04 0.02 0.01 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.18 0.10 0.13 0.14 0.08 0.08 0.02 0.01 0.01 0.00 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 13 1.78 8.36 9.41 6.50 5.48 8.70 6.30 3.59 8.01 9.62
Invested Capital Turnover		 0.23 0.23 0.25 0.25 0.15 0.36 0.04 0.01 0.02 0.00 0.00
Increase / (Decrease) in Invested Capital		 -8.44 -16 -3.96 -3.19 -6.87 3.70 0.33 -3.11 -2.92 2.52 0.93
Enterprise Value (EV)		 31 -20 -2.57 -8.10 -5.48 15 -0.08 11 -141 35 -22
Market Capitalization		 33 36 42 29 25 35 13 16 21 178 195
Book Value per Share		 $0.29 $1.10 $5.73 $5.00 $4.00 $2.81 $2.30 $1.29 $15.86 $3.18 $4.46
Tangible Book Value per Share		 $0.29 $1.10 $5.73 $5.00 $4.00 $2.81 $2.30 $1.29 $15.86 $3.18 $4.46
Total Capital		 16 58 54 47 37 26 22 12 165 151 227
Total Debt		 0.54 1.05 0.84 0.62 0.00 0.28 0.14 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -1.88 -56 -44 -37 -30 -20 -13 -5.71 -161 -143 -218
Capital Expenditures (CapEx)		 0.09 0.07 0.13 0.05 0.10 0.06 -0.00 0.00 0.00 0.93 0.98
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -7.97 -7.42 -4.58 -4.68 -6.68 -4.67 -6.07 -7.08 -8.40 -6.22 -4.46
Debt-free Net Working Capital (DFNWC)		 -5.54 49 39 33 24 16 6.78 -1.37 102 90 103
Net Working Capital (NWC)		 -6.08 48 39 32 24 16 6.64 -1.37 102 90 103
Net Nonoperating Expense (NNE)		 1.38 9.65 -2.95 0.19 2.43 4.39 -2.34 3.30 -58 5.82 4.87
Net Nonoperating Obligations (NNO)		 -1.88 -56 -44 -37 -30 -20 -13 -5.71 -161 -143 -218
Total Depreciation and Amortization (D&A)		 0.99 0.94 1.90 0.97 0.92 0.77 0.76 0.77 0.74 0.73 0.76
Debt-free, Cash-free Net Working Capital to Revenue		 -194.56% -331.47% -175.80% -168.40% -441.57% -353.31% -1,606.11% -6,175.15% -7,321.14% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 -135.33% 2,194.93% 1,517.09% 1,174.22% 1,568.09% 1,216.60% 1,794.94% -1,193.76% 89,350.67% 0.00% 0.00%
Net Working Capital to Revenue		 -148.56% 2,148.00% 1,484.99% 1,152.07% 1,568.09% 1,195.74% 1,758.27% -1,193.76% 89,350.67% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.00) ($41.40) ($0.54) ($0.79) ($1.12) ($1.23) ($0.56) ($1.09) $0.50 ($0.87) ($0.35)
Adjusted Weighted Average Basic Shares Outstanding		 5.24M 552.15K 9.24M 9.26M 9.26M 9.26M 9.29M 9.29M 10.66M 19.31M 53.56M
Adjusted Diluted Earnings per Share		 ($1.00) ($41.40) ($0.54) ($0.79) ($1.12) ($1.23) ($0.56) ($1.09) ($0.21) ($0.87) ($0.35)
Adjusted Weighted Average Diluted Shares Outstanding		 5.24M 552.15K 9.24M 9.26M 9.26M 9.26M 9.29M 9.29M 77.86M 61.34M 53.56M
Adjusted Basic & Diluted Earnings per Share		 $0.00 ($41.40) $0.00 $0.00 $0.00 ($1.23) $0.00 $0.00 $0.00 ($0.87) $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 5.23M 922.55K 9.23M 9.23M 9.23M 9.29M 9.29M 10.41M 47.61M 50.95M 76.46M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.73 -13 -7.97 -7.14 -7.92 -7.01 -7.54 -6.81 -8.88 -11 -14
Normalized NOPAT Margin		 -294.00% -4,331.53% -844.13% -2,713.87% 0.00% -6,108.38% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -402.59% -7,493.75% -532.06% -2,787.69% 0.00% -9,934.52% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 -72.41 -298.71 -71.33 -81.80 -135.18 -161.70 -74.60 -156.40 1,035.61 -275.72 -316.41
NOPAT to Interest Expense		 -53.46 -169.64 -104.40 -76.69 -101.45 -98.85 -108.39 -105.87 -292.87 -173.95 -223.10
EBIT Less CapEx to Interest Expense		 -73.63 -299.58 -73.02 -82.36 -136.46 -162.48 -74.60 -156.40 1,035.61 -290.43 -332.05
NOPAT Less CapEx to Interest Expense		 -54.68 -170.51 -106.09 -77.25 -102.73 -99.63 -108.39 -105.87 -292.87 -188.65 -238.74
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

SAB Biotherapeutics (NASDAQ: SABS) continues to operate like a pre-revenue biotech, with cash, investments, and financing activity doing most of the heavy lifting. The latest quarter shows a much stronger liquidity position than a year ago, but the business is still burning cash and depends on outside funding to support operations.

What stands out in Q1 2026:

  • Total assets rose to $248.5 million, up sharply from $183.4 million in Q3 2025 and $71.4 million in Q1 2024, reflecting a much larger balance sheet.
  • Cash and short-term investments totaled about $107.4 million in Q1 2026, giving the company a sizable liquidity cushion.
  • The company reported no short-term debt at quarter-end, which lowers near-term balance sheet risk.
  • Cash and equivalents increased to $20.5 million from $29.4 million at the prior quarter, but combined liquid investments still remained substantial.
  • Interest and investment income of $1.05 million helped offset some of the operating losses.
  • Net cash from financing activities was a strong $89.9 million, indicating the company was able to raise meaningful capital.
  • The company’s quarterly operating losses have generally narrowed versus early 2024, although they remain large and inconsistent quarter to quarter.
  • Revenue remains extremely limited and irregular, with $0 in Q1 2026 after sporadic modest revenue in prior periods.
  • Q1 2026 net loss was still sizable at $18.9 million, or -$0.35 per share.
  • Operating cash flow was negative $14.3 million, showing the core business is still consuming cash rather than generating it.

Trend analysis over the last four years:

SAB Biotherapeutics has shown a clear pattern of being a development-stage company with minimal revenue, persistent operating losses, and recurring cash usage. In 2024, the company had small quarterly revenue in some periods, but that revenue did not materially change the overall loss profile. Operating expenses have generally remained elevated, driven by R&D and SG&A, while net income has stayed negative in most quarters.

The balance sheet has improved materially, though. At the end of Q1 2024, SAB had $71.4 million in total assets and $21.4 million in equity. By Q1 2026, total assets had climbed to $248.5 million and equity to $227.2 million. That increase appears tied largely to financing activity and the buildup of investment assets rather than profitable operations.

Liquidity is the main positive here. The company moved from a relatively modest cash position in early 2024 to a much stronger one by 2026, with significant holdings in short- and long-term investments. That should give it more runway. However, the large financing inflows also underscore a key risk: SAB still depends on capital markets to fund its research pipeline.

Bottom line: SAB Biotherapeutics has strengthened its balance sheet and appears better funded than it was a year ago, but the underlying business remains speculative. Until revenue becomes more consistent and operating cash burn improves, investors should view the stock as a high-risk biotech story rather than a company with proven earnings momentum.

07/11/26 09:55 PM ETAI Generated. May Contain Errors.

SAB Biotherapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, SAB Biotherapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

SAB Biotherapeutics' net income appears to be on an upward trend, with a most recent value of $13.27 million in 2025, falling from $20.12 million in 2020. The previous period was -$34.11 million in 2024.

SAB Biotherapeutics' total operating income in 2025 was -$48.95 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $48.95 million

Over the last 5 years, SAB Biotherapeutics' total revenue changed from $55.24 million in 2020 to $0.00 in 2025, a change of -100.0%.

SAB Biotherapeutics' total liabilities were at $21.32 million at the end of 2025, a 17.0% increase from 2024, and a 21.6% increase since 2020.

In the past 5 years, SAB Biotherapeutics' cash and equivalents has ranged from $8.90 million in 2024 to $56.57 million in 2023, and is currently $10.50 million as of their latest financial filing in 2025.

Over the last 5 years, SAB Biotherapeutics' book value per share changed from 1.54 in 2020 to 3.18 in 2025, a change of 107.1%.


Related Companies

Financial statements for NASDAQ:SABSW last updated on 7/9/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in coul...
Stansberry Research | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Better than SpaceX? Grab this ticker instead.
Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...
Brownstone Research | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel